Drug Trial Radar · NCT06214741
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
307
Actual
Start
Feb 6, 2024
Primary completion
Jul 29, 2025
Study completion Jan 28, 2026
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jan 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study in China is open to adults who are at least 18 years old who are living with overweight or obesity. People with a body mass index (BMI) of 28 kg/m\^2 or higher or 24 kg/m\^2 or higher with at least 1 weight related problem can join the study. The main purpose of this study is to find out whether a medicine called survodutide helps people with overweight or obesity. 2 different doses of survodutide are tested in this study. Participants are put into 3 groups by chance. Each participant has an equal chance of being in each group. 2 groups get different doses of survodutide. 1 group gets placebo. Participants get survodutide or placebo as injections under the skin once a week for about 19 months. Placebo injections look like survodutide injections but do not contain any medicine. Participants are in the study for about 21 months. During this time, there are 20 visits. 14 visits are in person at the study site. Where possible, 6 visits can be done by video call, or by phone in rare cases. During this time, doctors regularly measure participant's body weight. Results are compared between the survodutide groups and placebo group to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Obesity
- Overweight
Interventions
survodutideDrug
once weekly subcutaneous injection
Placebo matching BI 456906Drug
Once weekly subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in body weight from baseline to Week 52Time frame: At baseline and at Week 52.
- Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 52Time frame: At baseline and at Week 52.
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chao-Yang Hospital
Beijing, China
Peking University People's Hospital
Beijing, China
Beijing Pinggu Hospital
Beijing, China
The First Hospital of Jilin University
Changchun, China
The Second Hospital of Jilin University
Changchun, China
Changzhou Second People's Hospital
Changzhou, China
People's Hospital of Sichuan Province
Chengdu, China
Second Affiliated Hospital Chongqing Medical University
Chongqing, China
NanFang Hosptial
Guangzhou, China
Forth Clinical Hospital of Harbin Medical University
Harbin, China
Huzhou Central Hospital
Huzhou, China
Center Hospital of Jinan
Jinan, China
Jincheng General Hospital
Jincheng, China
Lishui Municipal Central Hospital
Lishui, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, China
Affiliated Hospital of Nantong University
Nantong, China
The First Affiliated Hospital of Ningbo University
Ningbo, China
Panjin Liao Oil Gem Flower Hospital
Panjin, China
Shanghai Fifth People's Hospital affiliated to Fudan University
Shanghai, China
Siping Central People's Hospital
Siping, China
Tianjin Medical University Chu Hisen-I Memorial Hospital
Tianjin, China
Tianjin Medical University General Hospital
Tianjin, China
Wuhan Union Hospital
Wuhan, China
The First Affiliated Hospital of Xi'an Medical University
Xi'an, China
The People's Hospital Of Xuancheng City
Xuancheng, China
Yichang Central People's Hospital
Yichang, China
Yueyang People's Hospital
Yueyang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.